MTSR - Metsera, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$55.50
DETAILS
HIGH:
$57.00
LOW:
$54.00
MEDIAN:
$55.50
CONSENSUS:
$55.50
DOWNSIDE:
21.28%
About Metsera, Inc. (https://metsera.com)
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Christopher Whitten Bernard | Co-Founder, President, Chief Executive Officer & Director | 1984 | $763,182 USD |
| Brian Hubbard | Chief Scientific Officer | 1973 | $582,969 USD |
| Gbolahan Amusa Benz | Executive Vice President of Strategic Finance & Investor Relations | 1974 | $496,798 USD |
| Christopher J. Visioli | Co-Founder, Chief Financial Officer & Chief Business Officer | 1976 | $292,308 USD |
| Daniel Hoey | Chief Technical Operations Officer | 1967 | – |
| Melissa Enbar | Chief Human Resources Officer | – | – |
| Michael Donovan | Chief Design Officer | – | – |
| Nancye Green | Chief Experience Officer | – | – |
| Paul L. Berns | Co-Founder & Lead Independent Director | 1967 | – |
| Steven Marso | Chief Medical Officer | 1968 | – |